Literature DB >> 17540619

Presentation of HCV antigens to naive CD8+T cells: why the where, when, what and how are important for virus control and infection outcome.

Vito Racanelli1, Tobias Manigold.   

Abstract

T cell-mediated protection against HCV depends on constantly activated effector CD8(+)T cells that control emergence, spread and expansion of the virus. Why these cells fail to contain HCV replication in 70-80% of the individuals who develop persistent viremia is not clear. Although many reviews have focused on HCV's ability to interfere with the process of antigen presentation by dendritic cells (DC), only few have discussed the mechanisms whereby HCV-derived antigens become available for presentation to naive CD8(+)T cells. The importance of these mechanisms has been recently brought to light by new insight into DC biology, antigen processing, HCV replication and the immune system's functional anatomy. This review explores the different immunological scenarios in which CD8(+)T cell responses against HCV may be initiated. It describes the critical factors limiting antigen sensing and capture by APC and antigen recognition by T cells, and discusses how these factors may favor chronicity of HCV infection. Despite the lack of critical detail and hard experimental proof, this review proposes a model whereby liver seclusion, unproductive infection of professional antigen presenting cells and lack of direct tissue damage hamper the launch of a virus-specific CD8(+)T cell response. The implications for vaccine development are also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17540619     DOI: 10.1016/j.clim.2007.04.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  7 in total

1.  Interaction between immunoglobulin allotypes and NK receptor genes in diabetes post-hepatitis C virus infection.

Authors:  Julio Granados-Montiel; Joaquin Zúñiga; Jose Azocar; Edmond J Feris; Daniel Terreros; Charles E Larsen; Olga P Clavijo; Alfredo Cruz-Lagunas; Derek Middleton; Chester A Alper; Janardan P Pandey; Edmond J Yunis
Journal:  Immunobiology       Date:  2010-11-05       Impact factor: 3.144

2.  A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection.

Authors:  John A Mengshol; Lucy Golden-Mason; Tomohiro Arikawa; Maxwell Smith; Toshiro Niki; Ryan McWilliams; Jessica A Randall; Rachel McMahan; Michael A Zimmerman; Manu Rangachari; Evgenia Dobrinskikh; Pierre Busson; Stephen J Polyak; Mitsuomi Hirashima; Hugo R Rosen
Journal:  PLoS One       Date:  2010-03-04       Impact factor: 3.240

Review 3.  Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Authors:  Yuzuru Ikehara; Masahiro Yamanaka; Takashi Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-06-17

Review 4.  Dendritic cells in hepatitis C infection: can they (help) win the battle?

Authors:  Angela Dolganiuc; Gyongyi Szabo
Journal:  J Gastroenterol       Date:  2011-02-17       Impact factor: 6.772

5.  Transmitted/founder hepatitis C viruses induce cell-type- and genotype-specific differences in innate signaling within the liver.

Authors:  Angela M Mitchell; Amy E L Stone; Linling Cheng; Kimberly Ballinger; Michael G Edwards; Mark Stoddard; Hui Li; Lucy Golden-Mason; George M Shaw; Salman Khetani; Hugo R Rosen
Journal:  MBio       Date:  2015-02-24       Impact factor: 7.867

6.  Plasmodium vivax Pv12 B-cell epitopes and HLA-DRβ1*-dependent T-cell epitopes in vitro antigenicity.

Authors:  Yoelis Yepes-Pérez; Carolina López; Carlos Fernando Suárez; Manuel Alfonso Patarroyo
Journal:  PLoS One       Date:  2018-09-10       Impact factor: 3.240

7.  Rapid antigen processing and presentation of a protective and immunodominant HLA-B*27-restricted hepatitis C virus-specific CD8+ T-cell epitope.

Authors:  Julia Schmidt; Astrid K N Iversen; Stefan Tenzer; Emma Gostick; David A Price; Volker Lohmann; Ute Distler; Paul Bowness; Hansjörg Schild; Hubert E Blum; Paul Klenerman; Christoph Neumann-Haefelin; Robert Thimme
Journal:  PLoS Pathog       Date:  2012-11-29       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.